Nuveen Asset Management LLC Has $116.55 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Nuveen Asset Management LLC cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,499,915 shares of the biotechnology company's stock after selling 221,143 shares during the period. Nuveen Asset Management LLC owned approximately 1.23% of Exelixis worth $116,547,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Blue Trust Inc. lifted its holdings in Exelixis by 134.7% during the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after acquiring an additional 8,208 shares in the last quarter. Raymond James Financial Inc. bought a new position in Exelixis during the fourth quarter worth about $17,046,000. Allspring Global Investments Holdings LLC lifted its holdings in Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after acquiring an additional 704,786 shares in the last quarter. Inspire Investing LLC lifted its holdings in Exelixis by 25.0% during the fourth quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock worth $1,221,000 after acquiring an additional 7,331 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in Exelixis by 4.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 505,289 shares of the biotechnology company's stock worth $16,826,000 after acquiring an additional 22,225 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent analyst reports. Truist Financial lifted their target price on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Citigroup lifted their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Oppenheimer lowered Exelixis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $41.00 to $33.00 in a report on Friday, January 24th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, StockNews.com lowered Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $38.94.

Insider Buying and Selling

In other Exelixis news, CMO Amy C. Peterson sold 72,776 shares of the firm's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the transaction, the chief marketing officer now owns 465,393 shares in the company, valued at $21,161,419.71. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George Poste sold 20,634 shares of the firm's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $45.99, for a total value of $948,957.66. Following the completion of the sale, the director now directly owns 169,020 shares in the company, valued at approximately $7,773,229.80. This represents a 10.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 520,942 shares of company stock valued at $22,930,002 over the last 90 days. 2.82% of the stock is owned by corporate insiders.

Exelixis Price Performance

Exelixis stock traded down $0.33 during trading hours on Tuesday, hitting $44.36. The company had a trading volume of 3,484,388 shares, compared to its average volume of 2,282,828. The firm has a market cap of $12.10 billion, a PE ratio of 25.06, a PEG ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a one year low of $20.14 and a one year high of $48.85. The firm has a 50-day moving average of $37.38 and a 200 day moving average of $35.91.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.